Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) Research & Development (2020 - 2025)

iSpecimen has reported Research & Development over the past 6 years, most recently at $527033.0 for Q4 2025.

  • Quarterly results put Research & Development at $527033.0 for Q4 2025, down 44.62% from a year ago — trailing twelve months through Dec 2025 was $2.2 million (down 38.82% YoY), and the annual figure for FY2025 was $2.2 million, down 38.82%.
  • Research & Development for Q4 2025 was $527033.0 at iSpecimen, down from $551104.0 in the prior quarter.
  • Over the last five years, Research & Development for ISPC hit a ceiling of $967831.0 in Q4 2023 and a floor of $361799.0 in Q2 2021.
  • Median Research & Development over the past 5 years was $688030.0 (2022), compared with a mean of $687559.6.
  • Biggest five-year swings in Research & Development: skyrocketed 75.69% in 2022 and later crashed 44.62% in 2025.
  • iSpecimen's Research & Development stood at $522551.0 in 2021, then soared by 41.69% to $740410.0 in 2022, then skyrocketed by 30.72% to $967831.0 in 2023, then dropped by 1.67% to $951667.0 in 2024, then crashed by 44.62% to $527033.0 in 2025.
  • The last three reported values for Research & Development were $527033.0 (Q4 2025), $551104.0 (Q3 2025), and $536311.0 (Q2 2025) per Business Quant data.